BioMS Medical Pivotal Multiple Sclerosis Trial Receives Fourth Positive Review From Data Safety Monitoring Board

EDMONTON, May 3 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that following the fourth meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. "The recommendation by the independent DSMB strengthens our confidence as we move towards the completion of our pivotal trial," said Kevin Giese, President of BioMS Medical.
MORE ON THIS TOPIC